For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd6689Ma&default-theme=true
RNS Number : 6689M Argent Biopharma Limited 30 April 2024
30 April 2024
Argent BioPharma Ltd
PDMR Notification
Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), wishes to advise
that the following Persons Discharging Managerial Responsibilities (PDMR) were
issued a combined 68,000 unlisted options. This notification is made in
accordance the UK Market Abuse Regulations.
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Amir Polak
2 Reason for the notification
(a) Position Chief Pharmaceutical Development Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity Argent BioPharma Ltd
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b) Identification Code (ISIN) AU0000326647
(c) Nature of transaction Grant of Options over Ordinary Shares
(d) Currency Price Volume Total
AUD 0.00 12,000 N/A
Aggregated information
AUD 0.00 12,000 N/A
(e) Date of transaction 26 April 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Yair Tal
2 Reason for the notification
(a) Position Chief Information Security Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity Argent BioPharma Ltd
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b) Identification Code (ISIN) AU0000326647
(c) Nature of transaction Grant of Options over Ordinary Shares
(d) Currency Price Volume Total
AUD 0.00 8,000 N/A
Aggregated information
AUD 0.00 8,000 N/A
(e) Date of transaction 26 April 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Yifat Steuer
2 Reason for the notification
(a) Position Chief Operating Officer and Deputy CEO
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity Argent BioPharma Ltd
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b) Identification Code (ISIN) AU0000326647
(c) Nature of transaction Grant of Options over Ordinary Shares
(d) Currency Price Volume Total
AUD 0.00 15,000 N/A
Aggregated information
AUD 0.00 15,000 N/A
(e) Date of transaction 26 April 2024
(f) Place of transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Itay Nissim
2 Reason for the notification
(a) Position Chief Supply Chain Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity Argent BioPharma Ltd
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Unlisted options exercisable at A$0.70 on or before 1 April 2029.
(b) Identification Code (ISIN) AU0000326647
(c) Nature of transaction Grant of Options over Ordinary Shares
(d) Currency Price Volume Total
AUD 0.00 12,000 N/A
Aggregated information
AUD 0.00 12,000 N/A
(e) Date of transaction 26 April 2024
(f) Place of transaction Outside a trading venue
-Ends-
Authorised for release by the Company Secretary, for further information
please contact:
Argent BioPharma Limited Argent BioPharma Limited
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6555 2950 +61 8 6555 2950
info@argentbiopharma.com (mailto:info@argentbiopharma.com) info@argentbiopharma.com (mailto:info@argentbiopharma.com)
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe / Zach Cohen Aimee McCusker / Adam Pollock
+44 203 934 6630 +44 203 179 5300
argentbiopharma@investor-focus.co.uk aimeemccusker@oberoninvestments.com
(mailto:argentbiopharma@investor-focus.co.uk) (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
(mailto:adampollock@oberoninvestments.com)
About Argent BioPharma
Argent BioPharma purpose is to address unmet medical needs through the
pioneering integration of Nanotechnology and Multidisciplinary research
methods. Our approach heralds a transformative shift in healthcare, combining
the power of multi-targeted drug therapies with precision nanoscale delivery
to enhance treatment efficacy while reducing side effects. Central to our
ethos is making these innovative treatments accessible, ensuring they reach
those underserved by current medical solutions. As we endeavor to become
globally recognized in the life science industry, we are committed to bridging
healthcare gaps, redefining industry standards, and providing impactful
solutions and hope to communities worldwide.
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHKZGFDDGLGDZM